BioCardia (BCDA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.94, +1.08% vs the prior close of $0.93.
- Volume 236.30K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BCDA rises 1.1% to $0.94. Closed at $0.94, +1.08% vs the prior close of $0.93. Day range $0.87–$0.97, opened at $0.94.
BCDA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BCDA rises 1.1% to $0.94
- Closed at $0.94, +1.08% vs the prior close of $0.93. Day range $0.87–$0.97, opened at $0.94.
- Volume was 236.30K shares, 0.9x its 50-day average of 262.26K.
- Price is -10.8% vs its 50-day average ($1.05) and -14.4% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 18% of that range, 47.8% below the 52-week high.
Oct 14, 2026 — BCDA slides 6.1% to $0.93, a 1-month low, 5 down days in a row
- Closed at $0.93, -6.06% vs the prior close of $0.99. Day range $0.91–$1.00, opened at $1.00.
- Volume was 146.40K shares, 0.5x its 50-day average of 274.98K — lighter than usual.
- Price is -11.8% vs its 50-day average ($1.05) and -15.4% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 17% of that range, 48.3% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — BCDA dips 2.9% to $0.99, a 1-month low, 4 down days in a row
- Closed at $0.99, -2.94% vs the prior close of $1.02. Day range $0.98–$1.03, opened at $1.02.
- Volume was 68.00K shares, 0.2x its 50-day average of 275.53K — lighter than usual.
- Price is -6.1% vs its 50-day average ($1.05) and -10.1% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 23% of that range, 45.0% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — BCDA dips 1.9% to $1.02, 3 down days in a row
- Closed at $1.02, -1.92% vs the prior close of $1.04. Day range $1.00–$1.04, opened at $1.04.
- Volume was 80.30K shares, 0.3x its 50-day average of 276.48K — lighter than usual.
- Price is -2.9% vs its 50-day average ($1.05) and -7.5% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 26% of that range, 43.3% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — BCDA dips 1.9% to $1.04
- Closed at $1.04, -1.89% vs the prior close of $1.06. Day range $1.02–$1.08, opened at $1.06.
- Volume was 101.90K shares, 0.4x its 50-day average of 276.30K — lighter than usual.
- Price is -0.7% vs its 50-day average ($1.05) and -5.8% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 28% of that range, 42.2% below the 52-week high.
Oct 8, 2026 — BCDA dips 2.8% to $1.06
- Closed at $1.06, -2.75% vs the prior close of $1.09. Day range $1.05–$1.09, opened at $1.07.
- Volume was 162.40K shares, 0.6x its 50-day average of 275.74K — lighter than usual.
- Price is +1.8% vs its 50-day average ($1.04) and -4.1% vs its 200-day average ($1.10).
- 52-week range $0.75–$1.80; today's close sits at 30% of that range, 41.1% below the 52-week high.
Oct 7, 2026 — BCDA rises 2.8% to $1.09
- Closed at $1.09, +2.83% vs the prior close of $1.06. Day range $1.03–$1.09, opened at $1.07.
- Volume was 167.80K shares, 0.6x its 50-day average of 276.92K.
- Price is +5.2% vs its 50-day average ($1.04) and -1.4% vs its 200-day average ($1.11).
- 52-week range $0.75–$1.80; today's close sits at 32% of that range, 39.4% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — BCDA dips 2.8% to $1.06
- Closed at $1.06, -2.75% vs the prior close of $1.09. Day range $1.05–$1.11, opened at $1.10.
- Volume was 113.40K shares, 0.4x its 50-day average of 280.93K — lighter than usual.
- Price is +3.0% vs its 50-day average ($1.03) and -4.2% vs its 200-day average ($1.11).
- 52-week range $0.75–$1.80; today's close sits at 30% of that range, 41.1% below the 52-week high.
Oct 5, 2026 — BCDA jumps 4.8% to $1.09, 3 up days in a row
- Closed at $1.09, +4.81% vs the prior close of $1.04. Day range $1.04–$1.09, opened at $1.06.
- Volume was 148.40K shares, 0.5x its 50-day average of 280.56K — lighter than usual.
- Price is +6.4% vs its 50-day average ($1.02) and -1.6% vs its 200-day average ($1.11).
- 52-week range $0.75–$1.80; today's close sits at 32% of that range, 39.4% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — BCDA rises 2.0% to $1.04
- Closed at $1.04, +1.96% vs the prior close of $1.02. Day range $1.03–$1.05, opened at $1.04.
- Volume was 52.50K shares, 0.2x its 50-day average of 284.96K — lighter than usual.
- Price is +2.0% vs its 50-day average ($1.02) and -6.2% vs its 200-day average ($1.11).
- 52-week range $0.75–$1.80; today's close sits at 28% of that range, 42.2% below the 52-week high.
BCDA latest news & SEC filings
Every SEC filing by or about BCDA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 1,000 shares at $1.03 (≈$1.03K) on Sep 29, 2026; now holds 384,885
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 1,900 shares at $1.05 (≈$2.00K) on Sep 23, 2026; now holds 383,885
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 800 shares at $1.09 (≈$872) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 5,400 shares at $0.93 (≈$5.02K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 1,900 shares at $0.92 (≈$1.75K) on Aug 13, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$1.61M (prior year -$2.05M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.40
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Altman Peter bought 5,000 shares at $0.78 (≈$3.90K) on Jul 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade BCDA
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 24, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.67% (largest 7.7%).
- Liquidity: about 245.65K shares (≈$230.91K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.94 vs a range of $0.75–$1.80 (18% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Peter Altman bought 1,000 shares on Sep 29, 2026.
- Latest filings: 8-K Oct 7, 2026; 8-K Oct 1, 2026; 8-K Sep 23, 2026.
- Share count: 15.14M shares outstanding (Aug 11, 2026), +161.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BCDA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.94 | 0.97 | 0.87 | 0.94 | 236.30K |
| Oct 14, 2026 | 1.00 | 1.00 | 0.91 | 0.93 | 146.40K |
| Oct 13, 2026 | 1.02 | 1.03 | 0.98 | 0.99 | 68.00K |
| Oct 12, 2026 | 1.04 | 1.04 | 1.00 | 1.02 | 80.30K |
| Oct 9, 2026 | 1.06 | 1.08 | 1.02 | 1.04 | 101.90K |
| Oct 8, 2026 | 1.07 | 1.09 | 1.05 | 1.06 | 162.40K |
| Oct 7, 2026 | 1.07 | 1.09 | 1.03 | 1.09 | 167.80K |
| Oct 6, 2026 | 1.10 | 1.11 | 1.05 | 1.06 | 113.40K |
| Oct 5, 2026 | 1.06 | 1.09 | 1.04 | 1.09 | 148.40K |
| Oct 2, 2026 | 1.04 | 1.05 | 1.03 | 1.04 | 52.50K |
| Oct 1, 2026 | 1.00 | 1.05 | 0.99 | 1.02 | 205.90K |
| Sep 30, 2026 | 1.04 | 1.04 | 1.01 | 1.01 | 90.70K |
| Sep 29, 2026 | 1.05 | 1.07 | 1.00 | 1.03 | 117.30K |
| Sep 28, 2026 | 1.05 | 1.09 | 1.04 | 1.04 | 159.20K |
| Sep 25, 2026 | 1.08 | 1.08 | 1.05 | 1.05 | 51.20K |
| Sep 24, 2026 | 1.03 | 1.09 | 1.03 | 1.07 | 122.50K |
| Sep 23, 2026 | 1.03 | 1.08 | 1.03 | 1.05 | 141.00K |
| Sep 22, 2026 | 1.03 | 1.10 | 0.98 | 1.05 | 497.40K |
| Sep 21, 2026 | 1.18 | 1.19 | 1.06 | 1.08 | 2.08M |
| Sep 18, 2026 | 1.12 | 1.21 | 1.10 | 1.17 | 169.90K |
About BioCardia
BioCardia (BCDA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SUNNYVALE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 925741.
BCDA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jim L. Allen | Director | Jul 7, 2026 |
| Peter Altman | President and CEO | Sep 30, 2026 |
| Andrew Scott Blank | Director | Jul 7, 2026 |
| Bill Facteau | Director | Jul 7, 2026 |
| Jay M Moyes | Director | Jul 7, 2026 |
| Simon H Stertzer | Director | Jul 7, 2026 |
| Marvin Slosman | Director | Jul 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Peter Altman | President and CEO | Sep 30, 2026 |
| Edward M Gillis | Senior Vice President, Devices | Jul 7, 2026 |
| David Mcclung | Chief Financial Officer | Jul 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 29, 2026 | Peter Altman | Buy | 1,000 | $1.03 |
| Sep 23, 2026 | Peter Altman | Buy | 1,900 | $1.05 |
| Sep 3, 2026 | Peter Altman | Buy | 800 | $1.09 |
| Aug 17, 2026 | Peter Altman | Buy | 5,400 | $0.93 |
| Aug 13, 2026 | Peter Altman | Buy | 1,900 | $0.92 |
| Jul 29, 2026 | Peter Altman | Buy | 5,000 | $0.78 |
| Jul 17, 2026 | Peter Altman | Buy | 500 | $0.83 |
| Jul 15, 2026 | Peter Altman | Buy | 1,500 | $0.86 |
| Jul 14, 2026 | Peter Altman | Buy | 2,800 | $0.88 |
| Jul 10, 2026 | Peter Altman | Buy | 1,000 | $0.94 |
| Jul 9, 2026 | Peter Altman | Buy | 1,000 | $0.90 |
| Jul 8, 2026 | Peter Altman | Buy | 5,500 | $0.97 |
| Jul 8, 2026 | Peter Altman | Buy | 5,400 | $0.96 |
| Jun 23, 2026 | Simon H Stertzer | Buy | 39,000 | $1.00 |
| Jun 22, 2026 | Simon H Stertzer | Buy | 70,200 | $0.92 |
BCDA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-8.23M | -1.23 | $-7.44M |
| Dec 31, 2024 | — | $-7.95M | -2.90 | $-7.89M |
| Dec 31, 2023 | — | $-11.57M | -8.19 | $-9.97M |
| Dec 31, 2022 | — | $-11.91M | -0.67 | $-10.56M |
| Dec 31, 2021 | — | $-12.62M | -0.75 | $-10.37M |
Latest balance sheet: total assets $4.75M, total liabilities $2.06M, cash $4.12M (as of Jun 30, 2026).
BCDA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $0.88 |
| May 15, 2026 | 8-K Item 2.02 (results) | $1.01 |
| Mar 24, 2026 | 8-K Item 2.02 (results) | $1.21 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.30 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $1.68 |
| May 14, 2025 | 8-K Item 2.02 (results) | $2.77 |
| Mar 26, 2025 | 8-K Item 2.02 (results) | $2.55 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $2.35 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BCDA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.